Author:
Yang Hongxia,Sun Chao,Ye Lifang,Xu Yuetong,Lin Sang,Peng Qinglin,Wang Guochun,Lu Xin
Funder
the National High Level Hospital Clinical Research Funding
Natural Science Foundation of Beijing Municipality
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Nishino I, Hilton-Jones D, Stenzel W, Allenbach Y, de Groot I, Amato A et al. 224th ENMC International Workshop: Neuromuscul Disord. 2017;28:87–99.
2. Allenbach Y, Benveniste O, Stenzel W, Boyer O. Immune-mediated necrotizing myopathy: clinical features and pathogenesis. Nat Rev Rheumatol. 2020;16:689–701.
3. Allenbach Y, Drouot L, Rigolet A, Charuel JL, Jouen F, Romero NB, et al. Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: Inconstant exposure to statin. Med (United States). 2014;93:150–7.
4. Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mammen AL. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum. 2010;62:2757–66.
5. Tiniakou E, Pinal-Fernandez I, Lloyd TE, Albayda J, Paik J, Werner JL, et al. More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutarylcoenzyme A reductase-associated autoimmune myopathy. Rheumatol (United Kingdom). 2017;56:787–94.